Trinity Delta view: May’s FDA clearance was a major validation of Parsortix’s utility; with numerous further studies endorsing its value as a diagnostic in multiple tumour settings. Management’s challenge is addressing these wide-ranging potential uses in a systematic, effective, and efficient manner. H122 results highlight the strategy to address a variety of distinct diagnostic segments, with both near- and longer-term objectives, is gaining momentum. The recent £18.9m equity raise removes near-term financial uncertainty. We value ANGLE at £506m ($658m), equivalent to 215p/share, with significant upside once Parsortix’s positioning becomes clearer.
29 Sep 2022
Trinity Delta Lighthouse: ANGLE
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trinity Delta Lighthouse: ANGLE
ANGLE plc (AGL:LON) | 14.0 -0.2 (-9.7%) | Mkt Cap: 36.5m
- Published:
29 Sep 2022 -
Author:
Franc Gregori | Lala Gregorek | Philippa Gardner -
Pages:
2
Trinity Delta view: May’s FDA clearance was a major validation of Parsortix’s utility; with numerous further studies endorsing its value as a diagnostic in multiple tumour settings. Management’s challenge is addressing these wide-ranging potential uses in a systematic, effective, and efficient manner. H122 results highlight the strategy to address a variety of distinct diagnostic segments, with both near- and longer-term objectives, is gaining momentum. The recent £18.9m equity raise removes near-term financial uncertainty. We value ANGLE at £506m ($658m), equivalent to 215p/share, with significant upside once Parsortix’s positioning becomes clearer.